PRKACB and Carney complex.

  title={PRKACB and Carney complex.},
  author={Antonella Forlino and Annalisa Vetro and Livia Garavelli and Roberto Ciccone and Edra London and Constantine A. Stratakis and Orsetta Zuffardi},
  journal={The New England journal of medicine},
  volume={370 11},
The authors report that a gain of function in the catalytic subunit beta of the cyclic AMP–dependent protein kinase (protein kinase A), resulting from the presence of four copies of PRKACB (instead of the normal two), may lead to a Carney complex phenotype. 

Figures from this paper

The Molecular Basis for Specificity at the Level of the Protein Kinase a Catalytic Subunit
Recently identification of isoform specific amino acid sequences, motifs and three dimensional structures have together provided new insight into how PKA at the level of the C subunit may act in a highly isoform-specific fashion.
PRKACA: the catalytic subunit of protein kinase A and adrenocortical tumors
The current understanding of the involvement of PRKACA in adrenocortical tumorigenesis, and the understanding of PKA's role in adrenOCortical lesions are summarized and potential therapeutic advances that can be made are discussed.
E pluribus unum? The main protein kinase A catalytic subunit (PRKACA), a likely oncogene, and cortisol-producing tumors.
  • C. Stratakis
  • Biology, Medicine
    The Journal of clinical endocrinology and metabolism
  • 2014
Substantial circumstantial evidence was found that MMAD/AIMAH/PMAH tissues showed allelic losses of the PRKAR1A gene and/or its 17q locus, and proof that increased cAMP signaling was involved in almost all benign cortisol- producing lesions, and especially the “garden variety” cortisol-producing adenoma (CPA), was lacking.
Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas.
It is unlikely that mutation at this locus is involved in the pathogenesis of sporadic somatotroph adenoma; however, gene amplification or mutations at other loci or in other components of the cAMP signalling pathway, while unlikely, cannot be ruled out.
Activating PRKACB somatic mutation in cortisol-producing adenomas.
It is demonstrated for the first time to the knowledge that a PRKACB mutation can lead to an adrenal tumor and another mechanism of PKA pathway activation in CPAs is described, which highlights the particular role of residue Ser54 for the function of Pka.
cAMP/protein kinase A signalling pathway and adrenocortical adenomas
  • C. Ronchi
  • Biology
    Current Opinion in Endocrine and Metabolic Research
  • 2019
PKA Cβ: a forgotten catalytic subunit of cAMP-dependent protein kinase opens new windows for PKA signaling and disease pathologies.
How the PRKACA and PRKACB genes have developed as paralogs that encode distinct and functionally non-redundant proteins is discussed to open new windows for PKA-induced disease pathologies.
Haploinsufficiency for either one of the type-II regulatory subunits of protein kinase A improves the bone phenotype of Prkar1a+/- mice.
Haploinsufficiency for either of PKA-II regulatory subunits improved bone phenotype of mice haploinsufficient for Prkar1a, in support of the hypothesis that the PRKAR2A and PRKar2B regulatory subunit were in part responsible for the bone phenotypeof Prkar 1a(+/-) mice.


Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex
It is concluded that germline mutations in PRKAR1A, an apparent tumour-suppressor gene, are responsible for the CNC phenotype in a subset of patients with this disease.
Carney complex and other conditions associated with micronodular adrenal hyperplasias.
Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome.
Genetic alterations of the catalytic subunit of PKA were found to be associated with human disease and Germline duplications of this gene resulted in bilateral adrenal hyperplasias, whereas somatic PRKACA mutations resulted in unilateral cortisol-producing adrenal adenomas.
Truncations of titin causing dilated cardiomyopathy.
Incorporation of sequencing approaches that detect TTN truncations into genetic testing for dilated cardiomyopathy should substantially increase test sensitivity, thereby allowing earlier diagnosis and therapeutic intervention for many patients with dilated heart disease.
Next generation sequencing in clinical diagnostics
  • Dr
  • Biology
  • 2012
Not since the introduction of the polymerase chain reaction (PCR) in the mid 1980s has a platform technology emerged with such potential to transform medical diagnostics.
A genetic variants database for arrhythmogenic right ventricular dysplasia/cardiomyopathy
An online database, providing information on variants in ARVD/C‐associated genes, was created and converted into the Leiden Open Variation Database (LOVD) format, a gene‐centered collection of DNA variations.
Clinical whole-exome sequencing for the diagnosis of mendelian disorders.
W whole-exome sequencing identified the underlying genetic defect in 25% of consecutive patients referred for evaluation of a possible genetic condition.
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing
It is recommended that laboratories performing clinical sequencing seek and report mutations of the specified classes or types in the genes listed here and encourage the creation of an ongoing process for updating these recommendations at least annually as further data are collected.
Leftdominant arrhythmogenic cardiomyopathy in a large family: associated desmosomal or nondesmosomal genotype? Heart Rhythm 2013;10:548-59
  • 2013